These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 23402814)

  • 1. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
    Yabuuchi S; Pai SG; Campbell NR; de Wilde RF; De Oliveira E; Korangath P; Streppel MM; Rasheed ZA; Hidalgo M; Maitra A; Rajeshkumar NV
    Cancer Lett; 2013 Jul; 335(1):41-51. PubMed ID: 23402814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
    Burkhart C; Fleyshman D; Kohrn R; Commane M; Garrigan J; Kurbatov V; Toshkov I; Ramachandran R; Martello L; Gurova KV
    Oncotarget; 2014 Nov; 5(22):11038-53. PubMed ID: 25402820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
    Rajeshkumar NV; Rasheed ZA; García-García E; López-Ríos F; Fujiwara K; Matsui WH; Hidalgo M
    Mol Cancer Ther; 2010 Sep; 9(9):2582-92. PubMed ID: 20660600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
    Zhang Y; Liu L; Fan P; Bauer N; Gladkich J; Ryschich E; Bazhin AV; Giese NA; Strobel O; Hackert T; Hinz U; Gross W; Fortunato F; Herr I
    Oncotarget; 2015 Apr; 6(12):9999-10015. PubMed ID: 25846752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel.
    Mato-Berciano A; Raimondi G; Maliandi MV; Alemany R; Montoliu L; Fillat C
    Oncotarget; 2017 Apr; 8(14):22700-22715. PubMed ID: 28186974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
    Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models.
    Mizuma M; Rasheed ZA; Yabuuchi S; Omura N; Campbell NR; de Wilde RF; De Oliveira E; Zhang Q; Puig O; Matsui W; Hidalgo M; Maitra A; Rajeshkumar NV
    Mol Cancer Ther; 2012 Sep; 11(9):1999-2009. PubMed ID: 22752426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JNK pathway inhibition selectively primes pancreatic cancer stem cells to TRAIL-induced apoptosis without affecting the physiology of normal tissue resident stem cells.
    Recio-Boiles A; Ilmer M; Rhea PR; Kettlun C; Heinemann ML; Ruetering J; Vykoukal J; Alt E
    Oncotarget; 2016 Mar; 7(9):9890-906. PubMed ID: 26840266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma.
    Shimamura T; Royal RE; Kioi M; Nakajima A; Husain SR; Puri RK
    Cancer Res; 2007 Oct; 67(20):9903-12. PubMed ID: 17942922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma.
    Cook N; Frese KK; Bapiro TE; Jacobetz MA; Gopinathan A; Miller JL; Rao SS; Demuth T; Howat WJ; Jodrell DI; Tuveson DA
    J Exp Med; 2012 Mar; 209(3):437-44. PubMed ID: 22351932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer.
    Harikumar KB; Kunnumakkara AB; Sethi G; Diagaradjane P; Anand P; Pandey MK; Gelovani J; Krishnan S; Guha S; Aggarwal BB
    Int J Cancer; 2010 Jul; 127(2):257-68. PubMed ID: 19908231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
    Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine.
    Jung DB; Yun M; Kim EO; Kim J; Kim B; Jung JH; Wang E; Mukhopadhyay D; Hammond E; Dredge K; Shridhar V; Kim SH
    Oncotarget; 2015 Mar; 6(7):4992-5004. PubMed ID: 25669977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
    Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
    PLoS One; 2012; 7(6):e38477. PubMed ID: 22723862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer.
    Wolfe AR; Robb R; Hegazi A; Abushahin L; Yang L; Shyu DL; Trevino JG; Cruz-Monserrate Z; Jacob JR; Palanichamy K; Chakravarti A; Williams TM
    Clin Cancer Res; 2021 Jan; 27(2):554-565. PubMed ID: 33087331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells.
    Ponnurangam S; Dandawate PR; Dhar A; Tawfik OW; Parab RR; Mishra PD; Ranadive P; Sharma R; Mahajan G; Umar S; Weir SJ; Sugumar A; Jensen RA; Padhye SB; Balakrishnan A; Anant S; Subramaniam D
    Oncotarget; 2016 Jan; 7(3):3217-32. PubMed ID: 26673007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
    Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
    Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer.
    Kang YW; Lee JE; Jung KH; Son MK; Shin SM; Kim SJ; Fang Z; Yan HH; Park JH; Han B; Cheon MJ; Woo MG; Lim JH; Kim YS; Hong SS
    Cancer Lett; 2018 Dec; 438():174-186. PubMed ID: 30217561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma.
    Park JK; Kim Y; Kim H; Jeon J; Kim TW; Park JH; Hwnag YI; Lee WJ; Kang JS
    Oncotarget; 2016 Nov; 7(46):75081-75093. PubMed ID: 27655706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.